Behavioral Intervention and Anti-Obesity Drug Therapy / 대한내과학회지
Korean Journal of Medicine
;
: 624-628, 2013.
Artículo
en Coreano
| WPRIM
| ID: wpr-162113
ABSTRACT
Obesity is associated with a reduction in life expectancy and an increase in mortality from cardiovascular diseases, cancer, and other causes. The U.S. Preventive Service Task Force (USPSTF) recommends screening all adults for obesity. Clinicians should offer or refer patients with a body mass index of 30 kg/m2 or higher to intensive, multicomponent behavioral interventions. Behavioral interventions can lead to a moderate weight loss and improvement in blood sugar and other risk factors for cardiovascular disease. Behavioral interventions decreased the incidence of diabetes diagnosis by about 50% over 2 to 3 years. Orlistat, phentermine, diethylpropion, phendimetrazine, mazindol have been approved as anti-obesity drugs by Korea Food and Drug Administration. The U.S. Food and Drug Administration approved lorcaserin and phentermine plus topiramate combination for treatment of obesity in 2012.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Fentermina
/
United States Food and Drug Administration
/
Benzazepinas
/
Glucemia
/
Enfermedades Cardiovasculares
/
Pérdida de Peso
/
Índice de Masa Corporal
/
Tamizaje Masivo
/
Morfolinas
/
Incidencia
Tipo de estudio:
Estudio de etiología
/
Estudio de incidencia
/
Estudio pronóstico
/
Factores de riesgo
/
Estudio de tamizaje
Límite:
Adulto
/
Humanos
País/Región como asunto:
Asia
Idioma:
Coreano
Revista:
Korean Journal of Medicine
Año:
2013
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS